FDA Cites Dreyer’s Grand Ice Cream, Inc. in 2026-09-29 Warning Letter — CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated
TL;DR
FDA issued a warning letter (CMS #727644) to Dreyer's Grand Ice Cream, Inc. on September 29, 2026, following an inspection of its Bakersfield, California facility (January 27–February 20, 2026) that identified serious violations of Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventive Controls regulations under 21 CFR Part 117. The agency determined that the company's frozen ready-to-eat ice cream cone products are adulterated because they were prepared, packed, or held under insanitary conditions, specifically finding that the facility's hazard analysis failed to identify environmental pathogen contamination (including Listeria monocytogenes) as a preventive control despite ongoing environmental monitoring data showing 19 Listeria positives and 8 confirmed L. monocytogenes positives as of February 5, 2026.
Argus analysis
# FDA Warning Letter Analysis: Dreyer's Grand Ice Cream, Inc.
## Violation Overview
On September 29, 2026, the FDA's Human Foods Program issued a warning letter to Dreyer's Grand Ice Cream, Inc. (Bakersfield, CA facility) following a January–February 2026 inspection. The agency determined that the company's frozen, ready-to-eat ice cream cone products were adulterated under section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act because they were prepared, packed, or held under insanitary conditions with potential contamination by filth or pathogens. The inspection revealed serious violations of Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventive Controls requirements.
## Regulatory Citations and Meaning
The warning letter cites 21 CFR Part 117, specifically Subparts A, C, D, E, F, and G covering hazard analysis and preventive controls. The primary deficiency involved 21 CFR 117.130(a)(1), which requires manufacturers to evaluate known or reasonably foreseeable hazards. The FDA found that Dreyer's failed to identify *Listeria monocytogenes* as a hazard requiring preventive controls despite documented environmental monitoring records from 2021–2026 showing continuous presence of the pathogen. The company's sanitation procedures existed on paper but were not adequately implemented; employees were observed using reusable gloves while handling trash and non-food surfaces, then touching ready-to-eat products without changing gloves or sanitizing. Section 301(uu) of the Act prohibits failure to comply with preventive controls provisions at covered facilities.
## Timeline and Industry Outlook
The company submitted corrective action responses on March 13 and April 13, 2026, which FDA reviewed before issuing the warning letter. Compliance officers in frozen dessert manufacturing should monitor whether Dreyer's issues a public recall, posts facility reinspection results, or faces follow-up FDA action. The sustained *Listeria* detection—19 positives and 8 confirmed *L. monocytogenes* cases through February 2026—suggests heightened regulatory scrutiny going forward.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Dreyer’s Grand Ice Cream, Inc. MARCS-CMS 727644 — September 29, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC DELIVERY Product: Food & Beverages Recipient: Recipient Name Ms. Kim Peddle Rguem Recipient Title CEO Dreyer’s Grand Ice Cream, Inc. 7301 District Blvd Bakersfield , CA 93313 United States kim.peddlerguem@us.froneri.com Issuing Office: Human Foods Program United States September 29, 2026 WARNING LETTER Re: CMS # 727644 Dear Ms. Kim Peddle Rguem: The United States Food and Drug Administration (FDA) inspected your manufacturing facility, located at 7301 District Blvd, Bakersfield, CA, 93313, between January 27 through February 20, 2026. During our inspection of your facility, an FDA investigator found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Based on FDA's inspectional findings, we have determined that your frozen, ready-to-eat (RTE) ice cream cone products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA's regulations through links on FDA's website at www.fda.gov. At the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483 (FDA-483), Inspectional Observations. FDA received your emails, dated March 13, 2026 and April 13, 2026, which outlined corrective actions taken in response to the FDA-483. After reviewing the inspectional findings and your corrective actions, we are issuing this letter to advise you of FDA’s concerns. Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C) 1. You did not appropriately evaluate a known or reasonably foreseeable hazard to determine whether it required a preventive control in your RTE ice cream cone products, as required by 21 CFR 117.130(a)(1). Specifically: You provided a copy of a document that you stated was your hazard analysis for “Round Top Drumsticks, (b)(4) ”, which considers the hazard of “Pathogen Contamination” such as “Listeria” and/or “Salmonella” at the following steps: “ (b)(4) ”. This document concludes that the hazard is not reasonably likely to occur, and it is not a significant hazard at each of the steps because your “sanitation prerequisite program controls this hazard by applying a validated cleani…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Dreyer’s Grand Ice Cream, Inc. had FDA enforcement actions before?
- Yes. Argus HQ has recorded 2 total FDA actions tied to Dreyer’s Grand Ice Cream, Inc.: 1 warning letter, 0 recalls, and 0 approval records.
- What FDA violations was Dreyer’s Grand Ice Cream, Inc. cited for?
- The FDA Warning Letter to Dreyer’s Grand Ice Cream, Inc. (issuing office: Human Foods Program) cites: CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Dreyer’s Grand Ice Cream, Inc. in 2026-09-29 Warning Letter — CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-dreyer-s-grand-ice-cream-inc-2026-09-29-cgmp
"FDA Cites Dreyer’s Grand Ice Cream, Inc. in 2026-09-29 Warning Letter — CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-dreyer-s-grand-ice-cream-inc-2026-09-29-cgmp.
Argus HQ Research. "FDA Cites Dreyer’s Grand Ice Cream, Inc. in 2026-09-29 Warning Letter — CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated." Digital Empire Holdings LLC. Accessed October 15, 2026. https://argushq.ai/fda/warning-letter/fda-wl-dreyer-s-grand-ice-cream-inc-2026-09-29-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_dreyer_s_grand_ice_cream_inc_2026_09_29_cgmp_2026,
title = {FDA Cites Dreyer’s Grand Ice Cream, Inc. in 2026-09-29 Warning Letter — CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-dreyer-s-grand-ice-cream-inc-2026-09-29-cgmp},
note = {Accessed: October 15, 2026}
}